Last Updated : January 9, 2025
Current status: Open
Dates: January 6, 2025, and will close on February 6, 2025
The drug Reimbursement Review process at Canada’s Drug Agency plays a critical role in the pathway that helps patients access new drugs. In June 2023, we signalled program improvements that could be explored or added to the process. Since that time, the organization has been engaging with all partners to identify additional improvements and new approaches.
The measures proposed in this consultation document are intended to accelerate patient access to proven new treatments and streamline our processes. We look forward to receiving feedback on these proposals and moving toward thoughtful implementation after assessing the feedback. We are seeking feedback from interested parties on the following 6 topics:
- proportionate review processes
- review and recommendation reporting
- deliberative process
- accelerated access pathways
- checkpoints with sponsors throughout the drug Reimbursement Review process
- application requirements for sponsor submissions.
The following documents are related to the proposed improvements.
| Document | Purpose of document | Target audiences |
|---|---|---|
| Proposed Improvements to the Reimbursement Review Process | Primary consultation document |
|
| Deliberative Framework for Expert Committees at Canada's Drug Agency | Deliberative framework to be used in expert committee deliberations |
|
| Proposed Summary of Clinical Evidence and Economic Evaluation Template for Pharmaceuticals With Anticipated Comparable Efficacy and Safety Tailored Reviews | New submission requirement |
|
| Proposed Consolidated Eligibility Inquiry Form | New and updated application forms |
|
How to participate
To provide comments on the proposal, use the feedback template.
Feedback must be received by 5:00 p.m. ET on February 6, 2025. For feedback to be considered, individuals and organizations must be identified by name in the template. One response per organization will be considered.
Contact us
Questions about the feedback process can be sent to [email protected].
Last Updated : January 9, 2025